Latest News on TechBio 🐬
🏵️ Proscia announced a 4️⃣0️⃣0️⃣% YoY growth in daily diagnoses
Proscia ➡️ 4️⃣0️⃣0️⃣% increase year-over-year. On July 16, 2025, Proscia was on track for 3️⃣2️⃣,0️⃣0️⃣0️⃣ patients to be diagnosed on its Concentriq software platform each day—a 4️⃣0️⃣0️⃣% increase year-over-year, a momentum that reflects the company’s strong role as a trusted partner to major laboratories worldwide as it helps them to unlock the clinical, operational, and financial value of AI-driven pathology at scale (Proscia Cements Leadership in Diagnostic Pathology with 400% Growth in Daily Cases - Proscia). This is mainly due to:
➡️ Launch of 24/7 Support Enhances Proscia’s Top Rated Customer Experience: Customers using Proscia-managed cloud instances of Concentriq can benefit from always-on, expert assistance through the company’s newest premium support offering.
➡️ New Application Suites Accelerate AI Adoption for High-Impact Use Cases: Proscia has introduced 5️⃣ application suites consolidating multiple AI tools into pre-configured offerings seamlessly available on Concentriq, for
Breast: Cancer detection and quantitative scoring for HER2, Ki-67, and ER/PR, aligned with current clinical guidelines
Prostate: Cancer detection, automated Gleason scoring, and metastasis prediction
Gastric: Cancer detection, H. pylori and chronic gastritis detection
Prognostic: Risk stratification and treatment planning based on tumor morphology and biomarker expression for colon and breast
Quality Control: Image artifact and quality assessments across 10+ indications, including IHC stain quality evaluation
➡️ Concentriq’s Deep LIS Interoperability Strengthens Role of Digital Pathology In High-Volume Workflows: Proscia’s professional services team has now integrated Concentriq with more than 1️⃣0️⃣0️⃣ laboratory information system (LIS) instances—including CoPath, Epic Beaker, NovoPath, LigoLab, and Orchard Harvest—across its global customer base. Bidirectional HL7 interfaces power robust connections that tightly align digital pathology with laboratory workflows, whether driven by Concentriq or the LIS.
➡️ Laboratories Generate Millions in 🆕 Revenue as Part of Proscia’s Diagnostic Network: Since Proscia established its diagnostic network in 2024, the company has enabled participating laboratories to capitalize on new high-margin revenue opportunities including:
Real-World Data (RWD) Monetization
AI Testbed for Real-World Validation
Pharmaceutical Services Offerings
Moreover on June 11, 2025, The 2025 Laboratory Leadership Report was published based on a survey conducted by The Dark Intelligence Group on behalf of Proscia, a report that captures insights from 360 senior professionals representing independent, hospital, and academic laboratories (Majority of Diagnostic Laboratory Leaders Bet Big on Digital Pathology and AI). Just a week before publishing this report (June 3, 2025) Proscia also announced its inclusion in Fierce Medtech’s “Fierce 15” of 2025 for its AI pathology leadership 🎩 across the precision medicine value chain (Fierce Medtech Names AI Pathology Leader Proscia to 2025 Fierce 15). (View the full Fierce 15 list here).
More specifically ➡️ Proscia is offering the Concentriq® platform that incorporates a portfolio of best-in-class applications, tools for building algorithms, and AI-native features into routine workflows, helping its user base of over ⬆️ 1️⃣2️⃣, 0️⃣0️⃣0️⃣ pathologists and scientists to drive efficiencies, identify novel biomarkers, and develop and deploy companion diagnostics. So far, Concentriq is trusted by 1️⃣6️⃣ of the top 2️⃣0️⃣ pharmaceutical companies.
Additionally, Proscia lately had also a series of high-impact milestones:
▶️ On May 30, 2025, Labcorp announced it adopted Concentriq LS to accelerate clinical trials and companion diagnostic development (Labcorp ramps up oncology R&D speed with advanced diagnostics and digital pathology).
▶️ Proscia launched Concentriq Embeddings to accelerate AI development with foundation models, demonstrating a 1️⃣3️⃣x efficiency gain.
▶️ The company introduced a real-world data offering enabling data scientists to leverage over 1️⃣0️⃣ million pathology images with associated clinical and genomic data to fuel their AI algorithms.
▶️ Finally in March 2025, the company announced 💲5️⃣0️⃣M in funding led by Insight Partners, alongside Alpha Intelligence Capital, Triangle Peak Partners, and more.
🏵️ BullFrog exclusive investor webinar scheduled for July 23, 2025
BullFrog announced an exclusive investor webinar 🎦 scheduled for July 23, 2025, at 4:15 p.m. ET. BullFrog AI Holdings (NASDAQ: BFRG) announced an exclusive investor webinar 🎦 scheduled for July 23, 2025, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Vin Singh discussing the company's AI-driven drug development platforms (BullFrog AI Reveals Next-Gen Drug Development Platform in Exclusive CEO Webinar - $204B Market Opportunity).
Key 🔑 highlights include:
the recently launched BullFrog Data Networks™ Solutions Library, powered by their proprietary bfLEAP™ causal AI engine, and
the new bfPREP™ module for automated data processing.
The company will also discuss its strategic partnership with Sygnature Discovery, aimed at expanding international presence in the 💲2️⃣0️⃣4️⃣ billion biopharma R&D market.
In particular on June 12, 2025, BullFrog announced a strategic collaboration with Sygnature Discovery, a leading UK-based contract research organization (CRO) specializing in drug discovery, that will introduce BullFrog Data Networks™ to Sygnature’s global client base of relevant biopharma companies. The collaboration is expected to greatly accelerate brand recognition and user uptake to generate between 💲1️⃣5️⃣-💲3️⃣0️⃣ M in revenue for BullFrog AI through 2028 (BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma Clients).
The BullFrog Data Networks™ accelerates the exploration of complex, high-dimensional, multi-modal datasets, uncovering hidden relationships and novel pathways critical to understanding disease biology. The platform supports vital research applications including early target identification, mechanism-of-action elucidation, patient stratification, drug repurposing, and clinical trial optimization.
Moreover on February 27, 2025, BullFrog AI announced its entry into a collaboration 🤝 agreement with Eleison Pharmaceuticals Inc, a Phase 3 oncology company focused on novel 🔶 chemotherapeutic treatments for rare cancers (BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial).
Bullfrog AI Holdings Inc, that through its subsidiaries operates as a digital biopharmaceutical company that focuses on AI/ML driven analysis of data sets, also offers bfLEAP™. Developed at the prestigious Johns Hopkins University Applied Physics Laboratory and exclusively licensed to BullFrog AI, bfLEAP™ is a unique graph analytic AI platform that rapidly detects anomalies and uncovers hidden associations within disparate, multimodal, and incomplete data sets.
At its core, the bfLEAP™ platform designed for biological and clinical data sets, is creating comprehensive data networks ready for in-depth analysis, and can be used for ➡️ drug discovery, ➡️ patient segmentation, ➡️ drug repurposing, ➡️ target discovery, and ➡️ enhanced clinical trial analysis.
Moreover on May 16, 2024, BullFrog announced significant advancements in its collaboration with the Lieber Institute for Brain Development (LIBD), including the identification of potential drug targets for multiple neuropsychiatric conditions. The collaboration between BullFrog AI and LIBD, announced in September 2023, leverages the bfLEAP™ platform to mine LIBD’s comprehensive brain 🧠 data, that includes 📍transcriptomic, 📍genomic, 📍DNA methylation, 📍cell-line, 📍clinical and 📍 imaging data from over 2️⃣8️⃣0️⃣0️⃣ brain samples. Early results announced in January 2024 highlighted the ability to stratify brain expression data, revealing biological subtypes within psychiatric disorders.
Apart from the LIBD collaboration progression, on October 09, 2024, BullFrog AI Announced Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114. In particular, the study provided 🆕 mechanistic evidence for the role of 🔶 BF-114 target 🎯 β2-spectrin in 📍obesity, 📍MASLD (non-alcoholic fatty liver disease), 📍MASH (metabolic dysfunction-associated steatohepatitis), and 📍HCC (liver cancer). The findings suggested that targeting β2-spectrin with BF-114 can prevent the progression of liver diseases. BF-114 is currently in the discovery phase.
💟 10x Genomics and A*STAR announced a collaboration
10x Genomics, Inc and the A*STAR Genome Institute of Singapore announced a research collaboration for ➡️ the Target Inference from Spatialomics & Histology Using Multimodal AI & Phenotypes (TISHUMAP) project. 10x Genomics, Inc (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS), announced a research collaboration for the Target Inference from Spatialomics & Histology Using Multimodal AI & Phenotypes (TISHUMAP) project (10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery).
This initiative will leverage 10x Genomics’ Xenium platform and advanced AI to analyze thousands of tissue samples with the goal of accelerating drug target discovery and enabling precision medicine for cancer and inflammatory diseases.
As part of the TISHUMAP study, A*STAR GIS and 10x Genomics will analyze up to 2️⃣, 5️⃣0️⃣0️⃣ formalin-fixed paraffin-embedded (FFPE) clinical tissue samples, including those from 👉 gastric, 👉 liver, and 👉 colorectal cancers.
Unlike traditional methods that require tissues to be broken down, 10x Genomics’ Xenium platform uniquely enables researchers to visualize gene activity directly within individual cells in intact tissues.
This approach generates a comprehensive and precise molecular-level map 🗺️, clearly illustrating how cells are positioned, interact and function within their natural biological context.
When combined with advanced AI, this powerful capability allows researchers to detect critical patterns across large datasets swiftly, significantly advancing the identification of novel biomarkers and drug targets.
💈 10X Genomics (10x Genomics Inc)
10x Genomics, Inc (NASDAQ:TXG) is a leading life-science technology company developing and selling instruments, consumables and software for analyzing gene expression in cells, and consists of three platforms:
the ➡️ Chromium platform for single cell sequencing that allows scientists to see the unique gene expression patterns of each cell;
the ➡️ Visium platform for spatial analysis of tissue sample for whole transcriptome analysis at single cell-scale resolution; and
the recently released ➡️ Xenium platform for subcellular spatial mapping, to characterize up to 5️⃣, 0️⃣0️⃣0️⃣ genes in cells and tissues with ultra precise single cell spatial imaging.
💟 Constellation, a NeuroAI company, emerges from stealth to build real-time models of human brain state
Constellation, a NeuroAI startup building the 1️⃣st foundation model of brain state, emerges from stealth 🥷. Constellation is a NeuroAI startup building the first foundation model of brain state 🧠, a powerful model trained on real-time neural, physiological, and behavioral data collected from instrumented spaces. The company is generating the richest multimodal dataset of human internal state ever collected. Its mission is to enable real-time, personalized neurotechnology to unlock new tools for mental health, cognition, and clinical trials; and to train AI systems that are safe and aligned because they actually understand people.
At Constellation they have raised funding and right now they are hiring two core roles:
🧱 Founding Engineer
Own the pipeline from sensor to cloud. USB, BLE, flaky SDKs, time sync, ingestion infra, QA tooling... it’s all yours. You’ll work across embedded, streaming, and backend systems to make sure data is clean, aligned, and usable.
🧠 Signal Processing Scientist
Turn raw neural HRV, EDA, video, + into interpretable features of cognition, emotion, arousal, and internal state. You'll build signal processing systems that are interpretable, robust, and worthy of powering the next generation of neurotech.
👉 Full descriptions here: [https://lnkd.in/gaiinuME].
🦚 AI-guided patient stratification improves outcomes and efficiency in the AMARANTH clinical trial
Sensitive tool for precise stratification, improving outcomes and decreasing sample size for a Alzheimer’s Disease (AD) clinical trial. In this study ➡️ AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer’s Disease clinical trial, a group of researchers demonstrated that their robust and interpretable AI-guided tool (predictive prognostic model, PPM) enhances precision in patient stratification, improving outcomes and decreasing sample size for an AD clinical trial.
More specifically, the AMARANTH trial of lanabecestat, a BACE1 inhibitor, was deemed futile, and as treatment did not change cognitive outcomes, despite reducing β-amyloid. However when employing the PPM, the researchers re-stratified patients precisely using baseline data and demonstrated significant treatment effects; that is, 4️⃣6️⃣% slowing of cognitive decline for slow progressive patients at earlier stages of neurodegeneration.
PPM is a robust and interpretable predictive prognostic model that extends beyond binary patient classification approaches and predicts not only whether but also how fast individuals at early stages of the disease or even pre-symptomatic stages may progress to AD.
PPM has been tested on independent real-world patient data from memory clinics and validated against longitudinal clinical outcomes.
PPM delivers an AI-guided marker of future cognitive health that predicts progression to AD more precisely than standard clinical assessments (i.e., cognitive data, MRI scan) and biomarkers typically used for patient inclusion in clinical trials (i.e., β-Amyloid positivity), offering potential to reduce misdiagnosis and optimize patient stratification.
In contrast, rapid progressive patients did not show significant change in cognitive outcomes.
These results provided evidence for AI-guided patient stratification that is more precise than standard patient selection approaches (e.g. β-amyloid positivity) and has strong potential to enhance efficiency and efficacy of future AD trials.
🦚 Eisai adopts Elix Discovery
Eisai will use Elix Discovery.Elix just announced that the pharma giant Eisai will use its all-in-one platform, Elix Discovery, to streamline and enhance the design of novel drug candidates (Eisai adopts Elix Discovery to accelerate AI-driven drug development). By partnering, the two Japanese companies aim to overcome the common challenges and speed up the drug development process, since Elix Discovery enables efficient compound design and helps narrow down synthesis and testing targets, reducing both time and resource investment.
Eisai Co., Ltd (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) (TYO: 4523) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.
➡️ Elix Discovery differentiates itself from other drug discovery platforms by providing access to multiple AI models trained using federated learning on data from 16 pharmaceutical companies, enabling powerful, and privacy-preserving insights across the industry.
Elix is an AI drug discovery company (CEO: Shinya Yuki/Headquarters: Tokyo Japan) that launched the “Elix Discovery” an all-in-one platform that provides everything needed for AI drug discovery, from models for property prediction and molecular design to AI consulting and implementation support.
The key 🔑 modules of Elix Discovery are: 👉 Elix Predict (activity against a target, physicochemical properties and ADMET properties), 👉 Elix Create (molecular design with desired properties: target activity, physicochemical properties, ADMET and ease of synthesis), and 👉 Elix Assist (methods for efficiently training AI models).
⭐ Maxwell Biosciences appointed Jon McClure as Chief Technology Officer
Maxwell Biosciences, a global health technology company utilizing Claromers™, has appointed Jon McClure as Chief Technology Officer.On July 17, 2025, Maxwell Biosciences, a global health technology company pioneering immune-inspired small molecules called Claromers™, announced 🆕 engineering leadership for its AI efforts. As part of this initiative, the company has appointed Jon McClure as Chief Technology Officer to accelerate the development of its AI-native platform for drug discovery and AI-empowered medical devices (Maxwell Biosciences Announces AI Department & Hiring of Jon McClure).
Maxwell Biosciences a Synthetic Immune System is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely 🆕 class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). More specifically, Maxwell's first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides.
🤏 Claromers are helical small molecules with amphipathic properties designed to mimic the human immune system: anti-inflammatory, high tissue tolerance, biostability, potent against established polymicrobial biofilms and currently untreatable infections.
Maxwell Biosciences has benefitted so far from over 💲3️⃣5️⃣M of non-dilutive grants and awards from governments around the world to validate its science and technology, including studies by US Govt-funded labs confirming that Maxwell's lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus.
In vivo safety data in human tissue and animal models (confirmed in collaboration with universities and independent labs) have showed that CLAROMER anti-infectives are well tolerated in vivo at 1️⃣,0️⃣0️⃣0️⃣ µg/mL concentration when injected under the skin; whereas, preclinical studies indicate activity against viruses starting at 7️⃣ µg/mL concentration. This is a potentially optimal therapeutic window for the subcutaneous treatment of viral infections in humans.
In February 2025, Maxwell Biosciences Secured US Military 🪖 Research Agreement to Combat Dengue Fever. In April 2025, Maxwell Biosciences Secured Anti-Diarrheal 🚽🧻 US Military Agreement. And in June 2025, Maxwell Targets $500B Cosmetics 💄 Market with Microbiome-Friendly Antiseptics.
⭐ Medical digital twins: enabling precision medicine and medical artificial intelligence
Digital twins 👬♊ originate in the field of engineering, in which a constantly updating virtual copy enables analysis, simulation, and prediction of a real-world object or process.
In this Health Policy paper Medical digital twins: enabling precision medicine and medical artificial intelligence, a group of researchers evaluated this concept in the context of medicine, and outlined 5️⃣ key components of the medical digital twin:
➡️ the patient,
➡️ data connection,
➡️ patient in-silico,
➡️ interface, and
➡️ twin synchronization.
I particular, they considered how various enabling technologies in multimodal data, AI, and mechanistic modelling will pave the way for clinical adoption and provide examples pertaining to 👉 oncology and 👉diabetes.
They also highlighted the role of data fusion and the potential of merging AI and mechanistic modelling to address the limitations of either the AI or the mechanistic modelling approach used independently. In particular, they highlighted how the digital twin concept can support the performance of large language models applied in medicine and its potential to address health-care challenges.
🐬 Dr. Antonio Manuel Lozano Ortega is joining Ruten
Dr. Antonio Manuel Lozano Ortega is joining Ruten, a Brain-Machine 🧠 Interface company. Dr. Antonio Manuel Lozano Ortega is joining Ruten as a Senior Scientific Consultant on Neuroengineering & AI. Dr. Antonio Manuel Lozano Ortega brings experience in pioneering translational and clinical neural interfaces, neural encoding/decoding, and computer vision from his work as the INTENSE consortium blindness co-leader at the Nederlands Herseninstituut, and as core-team member of the first-in-human cortical visual neuroprosthesis trials at the Biomedical Neuroengineering group.
In this role he will advise and contribute to Ruten's R&D on ML and computer vision pipelines, behavioral analysis, and neural decoding, while continuing his cortical visual neuroprostheses research in Spain.
Ruten is a Brain-Machine 🧠🤯 Interface company aiming to establish reconstructive treatments for conditions where standard options are either infeasible or ineffective.
🐬 BrachyDOSE, MedTech company working with ionizing radiation detection in oncology, raised
Lithuanian medtech startup BrachyDOSE secures backing 💰 for radiotherapy precision tool.The MedTech company working with ionizing radiation detection in oncology BrachyDOSE has secured 💶5️⃣5️⃣4️⃣,0️⃣0️⃣0️⃣ in funding to conduct clinical testing of its radiation dose measurement system used in cancer treatment (Lithuanian medtech startup BrachyDOSE secures backing for radiotherapy precision tool - ArcticStartup). The round was led by Coinvest Capital, contributing 💶3️⃣0️⃣0️⃣,0️⃣0️⃣0️⃣, with additional investment from BSV Ventures, as well as business angel groups LitBAN and EstBAN.
BrachyDOSE develops a combined hardware–software solution designed to measure and predict radiation exposure during radiotherapy. The investment will be used to complete CE and MDR certification, which are required for medical device commercialization in the European Union. The company has previously worked with hospitals in Lithuania to validate its technology in clinical settings.
🐬 Centaur, a foundation model to predict and capture human cognition
Create a computational model that can predict human behaviour in a wide range of settings.Centaur, is a computational model that can predict and simulate human behaviour in any experiment expressible in natural language (A foundation model to predict and capture human cognition), and was derived by fine-tuning a state-of-the-art language model on a large-scale dataset called ➡️ Psych-101.
Psych-101 has an unprecedented scale, covering trial-by-trial data from more than 6️⃣0️⃣,0️⃣0️⃣0️⃣ participants performing in excess of 1️⃣0️⃣,0️⃣0️⃣0️⃣,0️⃣0️⃣0️⃣ choices in 1️⃣6️⃣0️⃣ experiments.
Centaur not only captures the behaviour of held-out participants better than existing cognitive models, but it also generalizes to previously unseen cover stories, structural task modifications, and entirely 🆕 domains. Furthermore, the model’s internal representations become more aligned with human neural activity after fine-tuning.
Taken together, these results demonstrate that it is possible to discover computational models that capture human behaviour across a wide range of domains.
🐾 FDA updates list of “Medical Devices that Incorporate Digital Health Technologies”
The FDA just updated its lists of medical devices.The FDA just updated its lists of medical devices that incorporate digital health technologies, now including sensor-based digital health technologies (sDHTs) for the first time ➡️ 🔗 https://lnkd.in/d3wg_6rm, including:
an updated list of artificial intelligence-enabled medical devices,
an updated list of medical devices that incorporate augmented reality and virtual reality, and
a new list of sensor-based digital health technology medical devices.
While AI/ML-enabled and AR/VR devices have been tracked for some time, the addition of sDHTs is exciting since:
✅ It signals maturity. Reimbursement pathways for remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) are now well established and delivering real value, driving a double bottom line for care providers and the patients they serve.
✅ It reinforces regulatory clarity. Despite ongoing hesitation in life sciences to embrace digital endpoints, the FDA continues to demonstrate its ability to evaluate these tools and its commitment to supporting high-quality innovation in the digital era of medicine.
Key Highlights include:
📈 AI/ML dominates the landscape, with explosive growth starting around 2015,
🧠 Neurology is a leading therapeutic area across all three categories,
🫀 Cardiovascular dominates sDHT use cases and is also well represented in AI/ML and AR/VR,
🩻 Radiology leads in AI/ML and AR/VR, but is absent in sDHTs.
👉 🖇️ Medical Devices that Incorporate Sensor-based Digital Health Technology.
🐾 Clearly raised 💲1️⃣.4️⃣M
The Ukrainian startup Clearly raised 💲1️⃣.4️⃣M to expand globally and further develop its standalone AI therapy solution. Clearly (clearly.help) raised 💲1️⃣.4️⃣M (Ukrainian Startup Clearly Locks In New Funding to Support Mental Health). Clearly is a platform that matches psychotherapists and clients quickly and efficiently.
The Ukrainian startup Clearly, a fast-growing AI-powered mental health platform, has raised a seed funding to expand globally and further develop its standalone AI therapy solution.
Key 🗝️ highlights are ➡️
👯 Founders: Dima Kovalenko, Dmytro Marakhovskyi
📅 Founding year: 2022
🏭 Industry: HealthTech
💥 Problem: Limited access to personalized, effective psychological care, especially during crises and in underserved regions
📣 Solution: A hybrid platform offering AI-powered therapy, video sessions with licensed therapists, 24/7 AI companions, and specialized wellness programs for individuals and business
👥 Customers: Individuals and companies seeking accessible mental health solutions; over 20,000 therapy sessions per month
🌱 Stage: Seed stage, profitable
💰 Investment amount: €1.2 million
🚀 Funded by: Purple Ventures (lead), Pragmatech Ventures, angel investor Dmytro Orel, and $150K in non-equity grants